Fed Report Calls on NIH to Blaze Personalized Medicine Trail


Personalized Medicine Watch by John Russell

October 14, 2008 | It’s a busy time on the personalized medicine front. The recently-released federal government report, Priorities for Personalized Medicine, is gradually attracting attention. The state of Wisconsin last week jumped into the race to become a center for personalized medicine. And a group of technology providers has joined Scripps Translational Science Institute (STSI) to study to what extent people make behavioral changes when they are provided with genetic screening and information about their various risk factors.

Back in 2001, the President’s Council of Advisors on Science and Technology were instructed to develop   suggested policy around personalized medicine’s needs. The result, Priorities for Personalized Medicine, is not all that profound—“HHS, should join with the private sector to create a public/private sector ‘Personalized Medicine R&D Roadmap’ for coordinating discovery and translational research in personalized medicine”—but it’s a start.

NIH is urged to take in lead in directing “critical investments in the enabling tools and resources essential to moving beyond genomic discoveries to personalized medicine products and services of patient and public benefit.” Specifically, the report calls on NIH to spur efforts to develop an integrated nationwide network of standardized biospecimen repositories and to fund academic/industry projects addressing biomarker standardization, statistical methods.

Meanwhile Wisconsin governor Jim Doyle today announced the Wisconsin Genomics Initiative, a collaborative research effort among the Marshfield Clinic, Medical College of Wisconsin (MCW), University of Wisconsin School of Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). Wisconsin has long been a leader in genomic research. The Marshfield Clinic has undertaken the largest population-based genetic research project in the country which approximately 20,000 people have contributed their DNA and given researchers access to their complete electronic health records.

The other big news last week was the announcement that MicrosoftNavigenics, and Affymetrix would join forces with the Scripps Translational Science Institute (STSI) to launch a novel research study to assess the behavioral impact of personal genetic testing. The goal of the study is to discover if participating in personal genomic testing improves people’s health by encouraging them to make positive lifestyle decisions and medical monitoring.

The study will offer genetic scans by Navigenics to up to 10,000 employees, friends, and family of the nonprofit Scripps Health system in San Diego and monitor participants’ changes in behavior for two decades. Participants will report their lifestyle changes at 3- and 12-month intervals after they receive their Navigenics results. They will also take part in periodic health surveys over the next two decades. A complete database of genomic and clinical information will be maintained at the Scripps Genomic Medicine program. For more read the Bio-IT World article on the program.

Related Links
Priorities for Personalized Medicine report:
http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf.

The Wisconsin initiative:
http://www.eurekalert.org/pub_releases/2008-10/mc-gda101008.php
http://www.forbes.com/feeds/ap/2008/10/10/ap5537035.html

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Wiley
Wiley Chem Planner Synthesis Solved
Sponsored by Wiley


SGI and Intel
HPDA for Personalized Medicine
Sponsored by SGI and Intel


Intel
Transforming Large Scale Genomics and Collaborative Research
Sponsored by Intel


Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.